Qual é o preço para Galmed Pharmaceuticals Ltd. (GLMD)

O preço para Galmed Pharmaceuticals Ltd. (GLMD) é $0.5225

Qual é a capitalização de mercado para Galmed Pharmaceuticals Ltd. (GLMD)

A capitalização de mercado para Galmed Pharmaceuticals Ltd. (GLMD) é $4.32M

Galmed Pharmaceuticals Ltd. (GLMD) Índice P/V

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Ano	Rácio P/S	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Rácio P/S

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Rácio P/S	Diferença do rácio P/S	País
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	4.74	-	BE

Empresa

Rácio P/S

Diferença do rácio P/S

País